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Education and debate
National Institute for Clinical Excellence and its value
judgments
Michael D Rawlins, Anthony J Culyer
NICE has to make both scientific and social value judgments when appraising health technologies
and developing clinical guidelines for the NHS. Here, its chair and previous vice chair explain the
rationale behind the decisions
The National Institute for Clinical Excellence (NICE)
offers health professionals in England and Wales
advice on providing NHS patients with the highest
attainable standards of care.1 NICE gives guidance on
individual health technologies, the management of
specific conditions, and the safety and efficacy of inter-
ventional diagnostic and therapeutic procedures.
Guidance is based on the best available evidence. The
evidence may not, however, be very good and is rarely
complete. Those responsible for formulating the
NICE’s advice therefore have to make judgments both
about what is good and bad in the available science
(scientific value judgments) and about what is good for
society (social value judgments). In this article we focus
on the scientific and social judgments forming the crux
of the institute’s assessment of cost effectiveness. Scien-
tific value judgments and those relating to clinical
effectiveness are considered elsewhere.2
NICE’s approach to economic evaluation
On its own, clinical effectiveness is insufficient for
maintaining or introducing any clinical procedure or
process. Cost must also be taken into account. When
good evidence exists of the therapeutic equivalence
between two or more clinical management strategies,
the cheaper option is preferred (box 1).
Incremental cost effectiveness ratio
However, in most instances NICE is confronted with a
clinical management strategy that is better than
current standard practice but which costs more. NICE
must then decide what increase in health (compared
with standard practice) is likely to accrue from the
increase in expenditure. This is the incremental cost
effectiveness ratio. Such ratios can be expressed in
many ways. NICE’s preferred measure is the cost per
quality adjusted life year (QALY), but if appropriate
data on quality of life are not available, it uses alterna-
tives such as the cost per life year gained.
NICE rejects the use of an absolute threshold for
judging the level of acceptability of a technology in the
NHS for four reasons:
x There is no empirical basis for deciding at what
value a threshold should be set
x There may be circumstances in which NICE would
want to ignore a threshold
x To set a threshold would imply that efficiency has
absolute priority over other objectives (particularly
fairness)
x Many of the technology supply industries are
monopolies, and a threshold would discourage price
competition.
Rather than apply an arbitrary threshold, NICE
makes its decisions on a case by case basis, as shown
stylistically in the figure. As the incremental cost effec-
tiveness ratio increases, the likelihood of rejection on
grounds of cost ineffectiveness rises. The critical issues
Box 1: Cost minimisation
Oral and intravenous fludarabine are equivalent as
second line treatments for chronic lymphatic
leukaemia.3
The total (acquisition plus administration) costs over
four cycles are £3000 (£2700+£300) for oral
administration and £5300 (£2700+£2600) for
intravenous administration. Thus using oral
fludarabine rather than intravenous saves £2300 over
four cycles and the oral formulation is preferred.
Increasing cost/QALY (log scale)
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Relation between likelihood of a technology being considered as cost
ineffective plotted against the log of the incremental cost
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are the values of incremental cost effectiveness ratios at
inflexions A and B.4–6 Clinical management pathways
with ratios to the left of A would generally be regarded
as cost effective. Those with ratios to the right of B
would, if adopted, be likely to deny other patients (with
different conditions) access to more cost effective
treatments.
There is no empirical basis for assigning particular
values to A or B,7 but NICE and its advisory bodies
have taken the view that inflexion A occurs at around
£5000-£15 000/QALY and inflexion B at around
£25 000-£35 000/QALY. NICE would be unlikely to
reject a technology with a ratio in the range of £5000-
£15 000/QALY solely on the grounds of cost
ineffectiveness but would need special reasons for
accepting technologies with ratios over £25 000-
£35 000/QALY as cost effective. The main considera-
tions in making judgments about cost effectiveness for
ratios of £25 000-£35 000/QALY are:
x The degree of uncertainty surrounding the estimate
x The particular features of the condition and
population using the technology
x The innovative nature of the technology
x When appropriate, the wider societal costs and ben-
efits
x When appropriate, reference to previous appraisals.
The phrase “particular features of the condition
and the population using the technology” incorporates
matters that include the availability and clinical
effectiveness of other interventions for the condition,
particular public health issues (such as communicable
diseases), and special considerations of equity. Boxes 2
and 3 show examples of the application of some of
these principles.
Judgments about whether incremental cost effec-
tiveness ratios can be considered “reasonable” are
made by the independent members of NICE’s advisory
committees (particularly the appraisal committee) and
the guideline development groups. Membership is
drawn from clinicians and health managers working in
the NHS, technical experts (statisticians and health
economists), and patients or patient advocates.
Affordability
NICE does not take affordability into account when
making judgments about cost effectiveness. The term is
not a technical one, but we use it to mean that a
particular activity should be funded by increasing the
total funds available for health care rather than from
existing resources. This would imply increasing
taxation, borrowing on the markets, or diversion of
funds from another publicly funded activity. Affordabil-
ity, in this sense, is a matter for the government when
deciding the annual budget for the NHS. It is NICE’s
job to judge whether something ought to be purchased
from within the resources made available to the NHS.
The government could therefore judge a particular
intervention unaffordable for the NHS (because of the
large numbers who would be eligible for treatment)
even though NICE had judged it cost effective. In such
circumstances the government could respond in one
of two ways: the Department of Health and the Welsh
Assembly Government might formally advise the NHS
to ignore NICE’s advice; alternatively, ministers might
invoke one of the clauses in its directions to NICE stat-
ing that (in this particular case) it is required to take
account of “advice from ministers on available
resources.” So far, neither of these potential govern-
ment responses have been proposed or threatened.
Social value judgments
Social value judgments have a critical role if resources
are to be distributed with efficiency and equity. NICE
and its advisory bodies, however, have no particular
legitimacy to determine the social values of those
served by the NHS. To ensure that these values
resonate broadly with the public, NICE has formed a
Citizens Council.11 12
Box 2: Cost ineffectiveness
Anakinra for rheumatoid arthritis
Anakinra seems to be less effective than etanercept or
infliximab for rheumatoid arthritis.8 It costs
£7450/year for each patient. The incremental cost
effectiveness ratio for anakinra is estimated to be
£69 000/QALY for rheumatoid arthritis, which is an
unacceptable opportunity cost.
Interferon beta and glatiramer acetate for multiple
sclerosis
Interferon beta and glatiramer acetate reduce the
frequency and severity of relapse in
relapsing-remitting multiple sclerosis.9 The mid-range
estimates of the incremental cost effectiveness ratios
(£/QALY) depend on the time horizon examined:
+ 5 years = £580 000
+ 10 years = £308 000
+ 20 years = £70 000
The opportunity costs for each of these scenarios are
unacceptable.
Box 3: Cost effectiveness
Imatinib is licensed for the treatment of chronic
myeloid leukaemia in the chronic phase (after failure
of interferon alfa)10 and in the accelerated and blast
crisis phases (for those not treated earlier with
imatinib).
The mid range estimates of the incremental cost
effectiveness ratios (£/QALY) are:
+ 37 000 for the chronic phase
+ 38 400 for the accelerated phase
+ 49 000 for the blast crisis phase.
In the absence of any effective alternative treatment
(apart from bone marrow transplantation) imatinib
was considered to be cost effective in the chronic
phase after interferon alfa. Denial of imatinib in the
accelerated phase was considered to be inconsistent
because the ratio was similar to that for the chronic
phase
Denial of imatinib to patients in the blast cell phase
was considered unfair. Patients at this advanced stage
could reasonably have expected, in view of the
decisions made already, to have had the opportunity of
treatment with imatinib at an earlier stage of their
condition. The fact that they were not given this
chance would have been due to failings in the
healthcare system. On grounds of equity, therefore, it
was considered that imatinib should be available to
patients in the blast cell phase of chronic myeloid
leukaemia who had not previously been treated with
the drug.
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Efficiency
A fundamental value judgment is that efficiency in
health care involves maximising the health of the
population subject to the resources available. The main
social value judgments regarding efficiency relate to
the measure of health used and to the scope of costs
and benefits. NICE uses the QALY as the principal
measure of health outcome. This measure embodies
the important social value judgment that to count only
gains in life expectancy, without considering the quality
of the additional life years, omits important dimen-
sions of human welfare.11 The QALY has the
advantage of having been extensively validated in
experimental conditions.13–17 The main value judg-
ments embodied in QALYs are that health related
quality of life can reasonably be captured in terms of
physical mobility, ability to self care, ability to carry out
activities of daily living, absence of pain and
discomfort, and absence of anxiety and depression.
NICE believes that, while differential productivity at
work should be considered, it ought not be used to dis-
advantage people who are not in regular paid employ-
ment, including children and those who are retired.11 It
needs to explore how best to reflect productivity effects
without causing inequity in the ways in which services
are allocated.
It is sometimes held that NICE ought to give a
higher priority to novel treatments for conditions for
which no alternative specific forms of therapy are cur-
rently available, or to conditions associated with social
stigma such as mental illness or sexually transmitted
diseases.11 These, too, are social value judgments that
need to be considered in more detail in the future.
Equity
Equity lies at the heart of the NHS. Lack of equity (in
the form of so called postcode prescribing) was one of
the reasons why NICE was established. Much of the
philosophical literature on equity is far from being
applicable to the real world.18 19 NICE has therefore
had to make its own judgments. For NICE, equity also
refers to fairness in the ways in which the costs and
benefits of available care are distributed among all
those who use the NHS.19–21 NICE’s recommendations
are intended to apply across the whole of England and
Wales, regardless of where people live or work. Thus,
NICE has made the social value judgment that local
variations in cost ought not to result in variations in
availability of health care.11
Value judgements about equity are often implicit
within both clinical and cost effectiveness analyses. An
assumption that underlies most of NICE’s technology
appraisals has been that “a QALY is a QALY is a
QALY.” By this NICE means that a QALY gained or
lost in respect of one disease is equivalent to a QALY
gained or lost in respect of another. It also means that
the weight given to the gain of a QALY is the same,
regardless of how many QALYs have already been
enjoyed, how many are in prospect, the age or sex of
the beneficiaries, their deservedness, and the extent to
which the recipients are deprived in other respects
than health. The decision to give no differential weight
is the result of a social value judgment that an
additional adjusted life year is of equal importance for
each person.12
The Citizens Council has also considered how
NICEmight take account of age in its considerations of
clinical and cost effectiveness.12 The council recom-
mends that age should be taken into account when it is
an indicator of either risk or benefit. It does not recom-
mend, though, that NICE should be more generous in
its judgments of cost effectiveness merely because of
individuals’ social roles or age.
Conclusions
The scientific value judgments made by NICE remain,
ultimately, those developed and enunciated by the
knowledge, experience, and expertise of the board
members and its independent advisory bodies (the
appraisal committee, the interventional procedures
advisory committee and the guideline development
groups). NICE hopes that the NHS’s scientific and
clinical community will agree with the basis for these
judgments. Similarly, it hopes that the social value
judgments will resonate acceptably across the whole
community.
In the absence of other relevant information, NICE
will have to make its own social value judgments and be
held accountable for them. Explicit discussion of the
key issues will greatly aid in this process. Underlying all
the decisions, however, is one fundamental social value
judgment: that advice from NICE to the NHS should
embody values that are generally held by the
population that the NHS serves.
Contributors and sources: MDR has been chair of NICE since
1999 and AJC was vice chair from 1999 to 2003. The article was
conceived and written by both authors. MDR is the guarantor.
Competing interests: None declared.
1 National Institute for Clinical Excellence.A guide to NICE. London: NICE,
2003.
2 National Institute for Clinical Excellence. Scientific and social value
judgements. London: NICE, 2004. www.nice.org.uk/Pdf/boardmeeting/
brdmay04item6.pdf (accessed 15 Jun 2004).
3 National Institute for Clinical Excellence. Guidance on the use of fludarab-
ine for B-cell chronic lymphatic leukaemia.London: NICE, 2002. (Technology
appraisal No 29.) www.nice.org.uk/page.aspx?o = 22179 (accessed 25 Jun
2004).
4 Weinstein ML. From cost effectiveness ratios to resource allocation:
where to draw the line. In: Sloan FA, ed. Valuing health. Cambridge: Cam-
bridge University Press, 1995.
5 Towse A, Pritchard C, Devlin N, eds. Cost effectiveness thresholds: economic
and ethical issues. London:Office of Health Economics, Kings Fund, 2002.
6 Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new
technology have to be to warrant adoption and utilisation? Tentative
guidelines for using clinical and economic evaluations. CMAJ
1992;146:473-81.
Summary points
NICE exists to give health professionals advice on
providing their NHS patients with the highest
clinical standards of care
It undertakes its economic assessments using a
cost utility approach (cost per quality adjusted life
year)
Decisions about cost effectiveness are made on a
case by case basis
Judgment is needed to balance the tensions
between efficiency and equity
Education and debate
226 BMJ VOLUME 329 24 JULY 2004 bmj.com
7 Culyer AJ. The rationing debate: maximising the health of the whole
community. BMJ 1997;314:667-9.
8 National Institute for Clinical Excellence.Anakinra for rheumatoid arthritis.
London: NICE, 2003. (Technology appraisal No 72.) www.nice.org.uk/
page.aspx?o = 94670 (accessed 25 Jun 2004).
9 National Institute for Clinical Excellence. Beta interferon and glatiramer
acetate for the treatment of multiple sclerosis. London: NICE, 2002. (Technol-
ogy appraisal No 32.) www.nice.org.uk/page.aspx?o = 27588 (accessed 25
Jun 2004).
10 National Institute for Clinical Excellence.Guidance on the use of imatinib for
chronic myeloid leukaemia. London: NICE, 2002. (Technology appraisal No
50.) www.nice.org.uk/page.aspx?o = 37604 (accessed 25 Jun 2004).
11 NICE Citizens Council. Report of the first meeting: Determining clinical need.
London: NICE, 2003. www.nice.org.uk/pdf/FINALNICEFirstMeeting_
FINALReport.pdf (accessed 25 Jun 2004).
12 NICE Citizens Council. Report on age. London: NICE, 2003.
www.nice.org.uk/pdf/Citizenscouncil_report_age.pdf (accessed 25 Jun
2004).
13 Brazier JN, Jones N, Kind P. Testing the validity of the Euroqol and com-
paring it with the SF-36 health survey questionnaire. Qual Life Res
1993;2:169-80.
14 Anderson RT, Aaronson NK, Bullinger M, McBee WL. A review of the
progress towards developing health-related quality-of-life instruments
for international clinical studies and outcomes research.Pharmacoeconom-
ics 1996;10:336-55.
15 Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72.
16 Roset M, Badia X, Mayo NE. Sample size calculations in studies using the
EuroQol 5D. Qual Life Res 1999;8:539-49.
17 Kind P, Hardman G, Macran S. UK population norms for EQ-5D. York:
Centre for Health Economics, 1999 (Discussion paper No 172).
18 Culyer AJ, Wagstaff A. Equity and equality in health and health care. J
Health Econ 1993;12:431-57.
19 Culyer AJ. Economics and ethics in healthcare. J Med Ethics 2001;27:217-22.
20 Culyer AJ. Equity—some theory and its policy implications. J Med Ethics
2001;27:275-83.
21 Culyer AJ. Need: the idea won’t do—but we still need it. Soc Sci Med
1995;40:727-30.
Challenges for the National Institute for Clinical Excellence
Alan Maynard, Karen Bloor, Nick Freemantle
So far NICE has focused on evaluating new technologies rather than existing ones. But this
approach is creating inflationary pressure that the NHS cannot afford
Even with recent large increases in NHS expenditure,
acute funding difficulties continue to emerge. It is
essential that a national mechanism to prioritise new
and existing technologies is available to inform
decision making. The National Institute for Clinical
Excellence (NICE) was created to meet this need.1
However, despite Rawlins and Culyer’s essay on
consultation and equity,2 NICE has yet to mature into
the efficient prioritisation mechanism that is required
to ensure the best use of NHS resources.
Rationing
Rawlins has stated that there is “no role for NICE in the
rationing of treatments to NHS patients.”3 These weasel
words belie the inevitability of healthcare rationing,
which is ubiquitous in all healthcare systems. Rationing
involves depriving patients of care from which they
may benefit and which they wish to have4; this is
inescapably the business of NICE. Indeed, rationing is
the inevitable corollary of prioritisation, and NICE
must fully inform rationing in the NHS.
The issue is not whether but how to ration. The cri-
teria determining access to care depend on the health
goals society is seeking to achieve. Are we solely inter-
ested in efficient use of resources—maximising health
from a given budget? Or does society seek efficiency
and equity and, if so, is it prepared to sacrifice some
efficiency to achieve equity goals? The central nature of
NICE as a prioritisation (and hence rationing) body
means that four fundamental challenges emerge.
These challenges need to be managed carefully and
robustly if NICE is to prosper, as we discuss below.
Restricting access to NHS funding
Currently the role of NICE is too peripheral to the
NHS. For instance, the government should make it
impossible for the NHS to adopt expensive new
technologies until they are approved by NICE. The
additional benefits of most technologies are small—for
example, taxanes may add only a few more months to
life and have adverse side effects for cancer patients.
The function of NICE is to reach a consensus about
clinical and economic evidence. This does not imply
that only cost effective treatments should be funded
but that decisions to fund interventions under the NHS
should be taken after careful consideration of the best
possible information. Such consideration should be
done before, not after, the introduction of new
technologies.
Equity and efficiency trade-offs
Society is clearly not concerned only with efficiency
and using NHS budgets to maximise improvements in
population health. The NHS, in its usual fragmented
and implicit way, illustrates different value systems—for
example, by investing “inefficiently” in low birthweight
babies because our society values highly the lives of the
newly born. In some cases NICE has also operated
a rule of rescue approach to its recommendations
rather than one based solely on effectiveness or cost
effectiveness.5
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